-
The latest clinical data of Vertex/CRISPR gene editing therapy will be announced
Time of Update: 2021-05-23
Another abstract, code-named EP733, will be published in the video conference, titled "CTX001 for blood transfusion-dependent thalassemia: the ongoing CLIMB Thal-111 study of autologous Crispr-Cas9-modified CD34+ hematopoietic stem and progenitor cells Safety and effectiveness.
-
BeiGene has a good news!
Time of Update: 2021-05-23
Ibrutinib is used to treat adult relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or The phase 3 clinical trial of ALPINE in patients with small lymphocytic lymphoma (SLL) yielded positive results in the interim analysis.
-
Eimerizumab for the prevention and treatment of hemophilia A: Long-term follow-up results of the HAVEN1-4 study
Time of Update: 2021-05-22
During the study period, the average treated ABR of patients decreased during each 24-week treatment cycle.
In the study, the median treated target joint ABR of the patients in each 24-week treatment cycle was 0%.
-
How to reduce the incidence of lung injury in children after HCT?
Time of Update: 2021-05-22
The results showed that the cumulative incidence of lung injury after HCT in children was significantly different among the four clusters of patients (P<0.
-
Professor Wang Jianxiang: The newly approved DRd/DVd combination therapy in China helps achieve the goal of "deep remission and longer survival" for the first relapse of MM
Time of Update: 2021-05-22
For the treatment of relapsed/refractory MM, the "Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (Revised in 2020)" clearly stated that the goal of the first relapse treatment is to obtain the greatest degree of remission and prolong progression-free survival.
-
Exploring the T cell phenotype of HLH for the first time: T cell activation status can distinguish HLH from early sepsis
Time of Update: 2021-05-22
The results of the study showed that peripheral blood T cell activation status is easy to distinguish between HLH and early sepsis.
-
Good news for Gaucher's patients!
Time of Update: 2021-05-22
▎The editor of WuXi AppTec's content team recently, Takeda issued a press release stating that its Shire company's injection-use velaglucerase alfa (velaglucerase alfa, trade name: VEGRA ®, English trade name: Vpriv) was launched The application has been approved by the National Medical Products Administration (NMPA) of China and is suitable for long-term enzyme replacement therapy (ERT) for patients with Gaucher disease type 1.
-
Strong combination | four-drug regimen D-KRd has significant efficacy in NDMM patients
Time of Update: 2021-05-22
The results of a prospective, randomized, phase III clinical study showed that the first-generation proteasome inhibitor bortezomib, lenalidomide, and dexamethasone were induced by a three-drug regimen (VRd) combined with ASCT in NDMM, and the median progression-free survival The period (PFS) is up to 50 months.
-
Vibutuximab has great potential in newly diagnosed children with cHL
Time of Update: 2021-05-22
. Based on this, the researchers conducted the HLHR13 trial to evaluate the efficacy and safety of verbutoxib combined with chemotherapy in newly diagnosed cHL patients ≤18 years of age.
-
Interpretation of the 2021 CSCO Lymphoma 18F-FDG PET/CT Guidelines
Time of Update: 2021-05-22
The CSCO Lymphoma 18F-FDG PET/CT Guidelines (2021 version) have been updated in the overview, baseline PET, and post-treatment PET sections, and new PET-guided clinical strategies, PET/MRI, and independent imaging evaluation (IRC) related content have been added.
FDG PET/MRI is recommended by Level III experts.
-
Express | 78% of patients achieved complete remission, and the early clinical results of the IL-15 super agonist combination were positive
Time of Update: 2021-05-22
▎ WuXi AppTec content team editor May 4, 2021, ImmunityBio announced that its IL-15 super agonist complex Anktiva (N-803) combined with anti-CD20 monoclonal antibody therapy Rituxan (rituximab), in A 78% complete remission rate was achieved when treating patients with CD20 sensitive indolent non-Hodgkin lymphoma (iNHL, indolent non-Hodgkin lymphoma).
-
ROCK2 inhibitor Belumosudil is expected to bring new hope to patients with refractory cGVHD
Time of Update: 2021-05-22
CGVHD occurred after previous 1-3 line systemic treatment (including allogeneic bone marrow transplantation or allogeneic hematopoietic stem cell transplantation [allo-HSCT]) and received glucocorticoid therapy (with or without calcineurin inhibitor) And/or at the same time in vitro optical separation and replacement) patients aged ≥18 years old are eligible for enrollment.
-
Roche's blockbuster new drug Shuyou Lile® gains new indications in China, helping more patients with hemophilia A move towards a "zero-bleeding" free life
Time of Update: 2021-05-22
The approval of the non-inhibitor indication for Suyoulile® is based on three key phase three clinical trials HAVEN 3, HAVEN 4 and HAVEN 5 The results of the HAVEN 3[6] study showed that compared with patients who did not receive prophylactic treatment, adults aged 12 years and older who received emeicilizumab prophylaxis without factor VIII inhibitors and In adolescents, bleeding was reduced by 96% (p<0.
-
Please answer!
Time of Update: 2021-05-22
In clinical practice, when a patient's blood coagulation function is abnormal, how to use this characteristic of albumin to evaluate and treat the disease?
-
Interpretation of the updated key points of the 2021 CSCO Children and Adolescent Lymphoma Guidelines
Time of Update: 2021-05-22
Based on the results of this study, the 2021 version of the CSCO Children and Adolescent Lymphoma Guidelines recommends this program as a level II recommendation in the part of relapsed or refractory (R/R) HL.
-
Verbutuximab combined with DHAP in the treatment of R/R cHL shows considerable efficacy
Time of Update: 2021-05-22
Professor Marie José Kersten and others have carried out a phase II clinical study to evaluate the combination of verbutuximab (BV) and DHAP (dexamethasone, cisplatin, and cytarabine) regimens in relapsed or refractory classics Efficacy and safety in patients with type Hodgkin’s lymphoma (R/R cHL).
-
Blood | Using iPS cells in vitro hematopoietic cell differentiation system to study hereditary aplastic anemia caused by gene defects related to formaldehyde metabolism
Time of Update: 2021-05-22
The mutation of ALDH2 (Aldehyde Dehydrogenase 2, acetaldehyde dehydrogenase 2) and ADH5 (Alcohol Dehydrogenase 5, alcohol dehydrogenase 5) causes the formaldehyde produced in the process of hematopoietic differentiation cannot be decomposed normally, DNA damage is accumulated, and then induced Aplastic anemia occurs and eventually develops into leukemia.
-
Phase III clinical trial data of a new drug for the treatment of renal anemia was announced, and the results were surprising
Time of Update: 2021-05-22
Researchers mainly compared the effectiveness and safety of Vadaustat and erythropoietin (ESA) alfa epoetin in patients with non-dialysis chronic kidney disease.
The primary safety endpoint of the trial was the proportion of patients who had a major adverse cardiovascular event (MACE) for the first time and the associated risk ratio (HR).
-
Key points of the updated CSCO guidelines for diagnosis and treatment of hematological malignancies
Time of Update: 2021-05-22
From April 23rd to 24th, the 2021 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was successfully held. At the meeting, Professor Gong Tiejun from the Harbin Institute of Hematolo
-
Abatacept can effectively prevent acute graft-versus-host disease
Time of Update: 2021-05-22
The results of the study in patients receiving HLA8/8 URD allo-HSCT, using Abatacept compared with placebo combined with CNI+MTX to prevent GVHD, can significantly reduce the incidence of aGVHD.
